Last reviewed · How we verify
NCT06851299
The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.
Phase 2 trial testing trop2-ADC in Metastatic Triple-negative Breast Cancer in 60 participants. Currently enrolling.
30 April 2027
Quick facts
| Lead sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 March 2025 |
| Primary completion | 30 April 2027 |
| Estimated completion | 29 February 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- trop2-ADC
- ADC +anti-angiogenic drug — full drug profile →
- ADC + PD1 monoclonal antibody +anti-angiogenic drug — full drug profile →
Conditions studied
- Metastatic Triple-negative Breast Cancer — all drugs for Metastatic Triple-negative Breast Cancer →
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Who can join
Adults 18 to 70, female only, with Metastatic Triple-negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, multicenter, randomized controlled study aimed at evaluating the efficacy and safety of Trop2-ADC monotherapy or immune combination strategy in the treatment of advanced triple-negative breast cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Emerging Protein Targets in Triple-Negative Breast Cancer: Beyond Conventional Therapy
Previtali A, Guardamagna I, Calandra S, Shakarami M, et al · · 2026
Verify or expand the search:
- PubMed search for NCT06851299
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metastatic Triple-negative Breast Cancer
Currently open trials in the same condition.
- NCT05227664 — A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer · Phase 2 · active not recruiting
Other Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials
Trials by the same sponsor.
- NCT07168083 — Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression · not yet recruiting
- NCT07413497 — A Prospective Observational Clinical Study on Exploring the Value of Surgical Excision Combined With 32P Application in · not yet recruiting
- NCT07461077 — Noninvasive Implantation Potential vs Morphology-Based Selection in IVF Single Blastocyst Transfer · NA · not yet recruiting
- NCT07533526 — Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous I · NA · not yet recruiting
- NCT07408648 — A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06851299 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Last refreshed: 28 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06851299.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing